…neau, Quebec; and Dr. Paul Giacomini, Associate Director of the MS clinic, Montreal Neurological Institute, Montreal, Quebec. Part 1: Download Podcast Part 2: Download Podcast…
…ity of recovery was examined in a pooled analysis of 505 patients from the FREEDOMS/FREEDOMS II trials (Reder et al. ECTRIMS 2017; abstract P1186). At 8 years, 54.4% of patients on continuous fingolimod 0.5 mg had achieved CDI or minimal EDSS change, 17.2% had fluctuating EDSS scores, and 28.5% had worsening disability. Similar results were seen in the placebo/fingolimod switch groups: 45% were improved/stable, 22.5% had fluctuating disability sco…
…(Schatzberg et al. J Clin Psychiatry 2014;75:1411-1418; free full text at www.psychiatrist.com/JCP/article/_layouts/ppp.psych.controls/BinaryViewer.ashx?Article=/jcp/article/Pages/2014/v75n12/v75n1209.aspx&Type=Article). In the study by Katona and colleagues, elderly subjects (mean age 70.6 years) treated with vortioxetine 5 mg/day showed improved processing speed, verbal learning and memory on cognitive testing (Katona 2012). The reference agent…
…ean Medicines Agency, Summary of product characteristics, August 22, 2017. Free full text at www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/004230/WC500234561.pdf No head-to-head trials have compared cladribine tablets with other disease-modifying therapies. To date, only one preliminary study from the MSBase group has examined this issue using a propensity score-matched analysis (Kalincik et al. ECTRIMS 2017; abstr…
…no permissions are required prior to use. As a courtesy, we would like to ask that you provide us with feedback after your presentation(s). This will help us to fine-tune free educational resources that NeuroSens develops in the future. Click here to complete the feedback questionnaire…